Latest Safety News

Spacetalk Ltd has completed a major pivot from hardware to a scalable software-as-a-service model, driving a 26% increase in active mobile subscribers and a 9% rise in annual recurring revenue to $12 million.

Dimerix Limited has completed recruitment for its pivotal ACTION3 Phase 3 trial targeting a rare kidney disease, secured positive FDA feedback on trial endpoints, and reported a solid cash position of AU$38.5 million at the end of 2025.

Bannerman Energy reports steady progress on its Etango Uranium Project with key construction milestones met and a strong cash position, while uranium market fundamentals continue to strengthen. The company targets a positive Final Investment Decision within the next 6 to 12 months.

Image Resources NL reported a strong finish to 2025 with record heavy mineral concentrate production and sales, alongside promising developments in its gold exploration and synthetic rutile innovation.

Cynata Therapeutics has completed enrolment in major clinical trials for osteoarthritis and acute graft versus host disease, with pivotal results expected in the second quarter of 2026. The company also strengthened its patent portfolio and secured additional funding to extend its operational runway.

Renascor Resources is advancing its government-backed Purified Spherical Graphite demonstration facility in Adelaide, poised to challenge China’s dominance in battery anode materials with an innovative HF-free process.

Genesis Minerals delivered record gold production and a robust cash build in December 2025, while accelerating development at its Tower Hill project ahead of schedule.

Biotron Limited has completed the acquisition of Sedarex Limited alongside a $2.5 million capital raising, while its lead Hepatitis B drug candidate BIT-HBV001 shows promising preclinical results outperforming current treatments.

Arovella Therapeutics has secured a crucial regulatory nod from the U.S. FDA, allowing its lead CAR-iNKT cell therapy, ALA-101, to enter first-in-human clinical trials targeting blood cancers.

INOVIQ Limited has completed a $10.2 million capital raise to accelerate development of its exosome-based ovarian cancer screening test and CAR-exosome therapeutics, alongside key leadership appointments and promising preclinical results.

Li-S Energy has made significant strides in Q4 2025, securing a major government grant, forging key defence partnerships, and commissioning Australia’s first lithium foil production line.

Imricor Medical Systems has achieved a major milestone with FDA clearance for its NorthStar Mapping System, the first MRI-native 3D cardiac mapping platform approved in the US. This approval positions Imricor at the forefront of MRI-guided cardiac procedures in the world’s largest electrophysiology market.